The China Food for Special Medical Purpose Market was valued at USD 2.27 billion in 2024, and is projected to reach USD 3.33 billion by 2030, rising at a CAGR of 6.58%. The growth is attributed to the aging population, increasing prevalence of chronic diseases, rising malnutrition rates, and supportive regulatory frameworks. These factors contribute to the expanding demand for specialized nutritional products tailored to meet the unique needs of various patient groups. For instance, in July 2022, Nestlé introduced China's first food for special medical purpose (FSMP) specifically designed for patients with tumor-related conditions, following a five-year approval process by Chinese regulatory authorities.
The rising prevalence of chronic diseases such as hypertension, diabetes, and cancer is another significant driver. These conditions often lead to complications such as malnutrition and weight loss, increasing the need for specialized nutritional interventions. FSMPs formulated to support individuals with chronic illnesses help manage symptoms, improve quality of life, and reduce healthcare costs associated with malnutrition and related complications.
The Chinese government maintained the regulatory framework for Foods for Special Medical Purposes (FSMPs), with growing advocacy for future reimbursement coverage. The regulatory oversight for FSMPs is managed by the National Medical Products Administration (NMPA), formerly the China Food and Drug Administration (CFDA), facilitating product approvals and supporting market growth. As of September 2024, China had 206 registered FSMPs; of these, 174 are domestically produced, while 32 are imported, with domestically produced products significantly outnumbering imported ones. Among the approved products, 153 are powdered, and the remaining 53 are liquid.
A total of 66 FSMP products were approved for registration in 2024, originating from 17 different provinces and regions across China. Jiangsu, Shandong, and Heilongjiang emerged as the top three contributors, with 21, 10, and 6 approvals, respectively. These figures represent 32%, 15%, and 9% of the total registrations for the year.
The COVID-19 pandemic impacted China’s FSMP market by accelerating the demand for clinical nutrition products amid increased health awareness and medical needs. During the pandemic, the focus on patient care for vulnerable populations, such as those with chronic illnesses or compromised immunity, increased the reliance on specialized nutritional support to aid recovery and improve health outcomes. Several sectors faced economic downturns and cautious consumer spending, and healthcare and nutrition-related industries, including FSMP, saw growing attention due to their critical role in disease management and prevention. In addition, the pandemic expedited digital transformation and modernization in China’s healthcare system, facilitating better distribution, remote consultations, and awareness of FSMP products. The challenges, such as disrupted supply chains and regulatory adjustments, influenced market dynamics. Overall, COVID-19 catalyzed increased clinical nutrition adoption in China, setting the stage for sustained growth in the FSMP market as part of the country’s broader healthcare recovery and modernization efforts.
This product will be delivered within 1-3 business days.
The rising prevalence of chronic diseases such as hypertension, diabetes, and cancer is another significant driver. These conditions often lead to complications such as malnutrition and weight loss, increasing the need for specialized nutritional interventions. FSMPs formulated to support individuals with chronic illnesses help manage symptoms, improve quality of life, and reduce healthcare costs associated with malnutrition and related complications.
The Chinese government maintained the regulatory framework for Foods for Special Medical Purposes (FSMPs), with growing advocacy for future reimbursement coverage. The regulatory oversight for FSMPs is managed by the National Medical Products Administration (NMPA), formerly the China Food and Drug Administration (CFDA), facilitating product approvals and supporting market growth. As of September 2024, China had 206 registered FSMPs; of these, 174 are domestically produced, while 32 are imported, with domestically produced products significantly outnumbering imported ones. Among the approved products, 153 are powdered, and the remaining 53 are liquid.
A total of 66 FSMP products were approved for registration in 2024, originating from 17 different provinces and regions across China. Jiangsu, Shandong, and Heilongjiang emerged as the top three contributors, with 21, 10, and 6 approvals, respectively. These figures represent 32%, 15%, and 9% of the total registrations for the year.
The COVID-19 pandemic impacted China’s FSMP market by accelerating the demand for clinical nutrition products amid increased health awareness and medical needs. During the pandemic, the focus on patient care for vulnerable populations, such as those with chronic illnesses or compromised immunity, increased the reliance on specialized nutritional support to aid recovery and improve health outcomes. Several sectors faced economic downturns and cautious consumer spending, and healthcare and nutrition-related industries, including FSMP, saw growing attention due to their critical role in disease management and prevention. In addition, the pandemic expedited digital transformation and modernization in China’s healthcare system, facilitating better distribution, remote consultations, and awareness of FSMP products. The challenges, such as disrupted supply chains and regulatory adjustments, influenced market dynamics. Overall, COVID-19 catalyzed increased clinical nutrition adoption in China, setting the stage for sustained growth in the FSMP market as part of the country’s broader healthcare recovery and modernization efforts.
China Food For Special Medical Purpose Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the analyst has segmented the China food for special medical purpose (FSMP) market report based on route of administration, product, application, modules, and sales channel.Route of Administration Outlook (Revenue, USD Million, 2018-2030)
- Oral
- Enteral
Product Outlook (Revenue, USD Million, 2018-2030)
- Pills
- Powder
- Liquid
- Others (semisolid, semiliquid)
Application Outlook (Revenue, USD Million, 2018-2030)
- Chronic Kidney Disease
- Minimal Hepatic Encephalopathy
- Chemotherapy Induced Diarrhea
- Pathogen Related Infections
- Diabetic Neuropathy
- ADHD
- Depression
- Alzheimer's Disease
- Nutritional Deficiency
- Orphan Diseases
- Tyrosinemia
- Eosinophilic Esophagitis
- Food Protein Module-induced enterocolitis syndrome (Food Protein Module-induced enterocolitis syndrome (FPIES))
- Phenylketonuria (PKU)
- Maple syrup urine disease (Maple syrup urine disease (MSUD))
- Homocystinuria
- Others (Urea Cycle Disorder (UCD), Glycogen Storage Disease (GSD), etc.)
- Wound Healing
- Chronic Diarrhea
- Constipation Relief
- Protein Booster
- Dysphagia
- Pain Management
- Parkinson's Disease
- Epilepsy
- Other Cancer related treatments
- Severe Protein Allergy
- Cancer
- Cachexia
- Other (debilitating conditions, COPD, etc.)
Modules Outlook (Revenue, USD Million, 2018-2030)
- Amino Acid Module
- Protein Module
- Vitamin & Mineral Modules
- Fatty Acid based Modules
- Carbohydrate Modules
- Fiber Modules
- Ketogenic Modules
- Peptide based Modules
- Hypoallergic Modules
- Others (Electrolyte Module, etc.)
Sales Channel Outlook (Revenue, USD Million, 2018-2030)
- DTC Sales Channel
- Online Sales
- Retail Sales
- Institutional Sales
- Hospitals
- Others (Long-term Care Facilities, etc.)
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends, & Scope
Chapter 4. China FSMP Market: Route of Administration Estimates & Trend Analysis
Chapter 5. China FSMP Market: Product Estimates & Trend Analysis
Chapter 6. China FSMP Market: Application Estimates & Trend Analysis
Chapter 7. China FSMP Market: Modules Estimates & Trend Analysis
Chapter 8. China FSMP Market: Sales Channel Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies featured in this China Food for Special Medical Purpose market report include:- Danone (Nutricia)
- Nestlé
- Abbott
- Fresenius Kabi AG
- Mead Johnson (Reckitt Benckiser)
- Maifu Nutrition technology
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- H&H Group (Biostime)
- Synutra, Inc.
- Beingmate global
- Taicang Puyuan Pharmaceutical Co.
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
- Ainuo Instrument Co., Ltd.
- Kunyu Health Pharmaceutical Jiangsu Co., Ltd.
- Shijiazhuang Junlebao Taixing Dairy Co., Ltd.
- Jiangsu Dongze Special Medical Food Co., Ltd.
- Heilongjiang Feihe Dairy Co., Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 80 |
| Published | May 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 2.27 Billion |
| Forecasted Market Value ( USD | $ 3.33 Billion |
| Compound Annual Growth Rate | 6.5% |
| Regions Covered | China |
| No. of Companies Mentioned | 18 |
